Search Results for "sibutramine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for sibutramine. Results 1 to 6 of 6 total matches.
See also: Meridia

Sibutramine for Obesity

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998  (Issue 1022)
Sibutramine for Obesity ...
Sibutramine hydrochlorid monohydreate (Meridia - Knoll), which is structurally related to amphetamine, has been approved by the FDA for treatment of obesity. It is classified by the Drug Enforcement Agency (DEA) as a schedule IV controlled substance.
Med Lett Drugs Ther. 1998 Mar 13;40(1022):32 |  Show IntroductionHide Introduction

In Brief: Sibutramine (Meridia) Withdrawn

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2010  (Issue 1350)
In Brief: Sibutramine (Meridia) Withdrawn ...
The results of a postmarketing study of its cardiovascular safety have led to the removal of the weightloss drug sibutramine (Meridia) from the market in the US and Canada. It has also been withdrawn in Europe and Australia, but remains on the market in many other countries. The study that led the FDA to ask Abbott Laboratories to withdraw the drug randomized 10,744 overweight patients with cardiovascular disease, diabetes or both to sibutramine or placebo for a mean duration of 3.4 years. The primary endpoint (non-fatal myocardial infarction, nonfatal stroke, cardiovascular death or...
Med Lett Drugs Ther. 2010 Nov 1;52(1350):88 |  Show IntroductionHide Introduction

Dangerous Drugs

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004  (Issue 1197)
reason to use it. Sibutramine 4 (Meridia) is modestly effective in promoting weight loss in the short ...
At a US Senate hearing prompted by the withdrawal of Vioxx, an FDA officer cited 5 drugs as potentially dangerous. It may be useful to revisit Medical Letter reviews of these drugs.
Med Lett Drugs Ther. 2004 Dec 6;46(1197):97 |  Show IntroductionHide Introduction

Orlistat for Obesity

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 1999  (Issue 1055)
of orlistat concomitantly with phentermine (Medical Letter, 36:107, 1994) or with sibutramine (Meridia ...
Orlistat, a lipase inhibitor that decreases absorption of fat from the gastrointestinal tract, is now available for treatment of obesity.
Med Lett Drugs Ther. 1999 Jun 18;41(1055):55-6 |  Show IntroductionHide Introduction

Drugs That May Cause Psychiatric Symptoms

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
, hypersexuality, delusions Sibutramine (Meridia) Depression, psychosis, panic attacks Several reports 18 ...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.

Click here to view the free full article.
Med Lett Drugs Ther. 2008 Dec 15;50(1301):100-3 |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • May 30, 2022  (Issue 1651)
randomized controlled trial favored Orbera over a sham procedure with sibutramine (additional 2 kg weight ...
Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a 5-10% reduction in weight, which has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the preferred methods for losing weight, but long-term weight maintenance can be difficult. Several drugs and devices are FDA-approved for weight reduction and maintenance of weight...
Med Lett Drugs Ther. 2022 May 30;64(1651):81-8 |  Show IntroductionHide Introduction